--- title: "Effectiveness and safety of non-steroidal anti-inflammatory…" description: "Topical diclofenac is a safer and effective first-line option for knee osteoarthritis, while some oral NSAIDs are effective but carry higher risks, and…" url: "https://magellanlongevity.com/study/diclofenac_oa.md" canonical: "https://magellanlongevity.com/study/diclofenac_oa.html" html: "https://magellanlongevity.com/study/diclofenac_oa.html" type: "study" study_key: "diclofenac_oa" journal: "BMJ" year: 2021 pmid: "34642179" doi: "10.1136/bmj.n2321" citations: 1 updated: 2026-09-02 author: "Gabriel Radu, DO" author_credentials: "Physiatrist (PM&R). NY medical license 275110. NPI 1376861765." publisher: "Magellan Longevity" content_format: "markdown" --- # Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis [Home](https://magellanlongevity.com/) › [Research map](https://magellanlongevity.com/longevity-research-map.html) › Effectiveness and safety of non-steroidal… **HTML version:** https://magellanlongevity.com/study/diclofenac_oa.html · **In the Magellan app:** https://magellanlongevity.com/#/study/diclofenac_oa ## Citation | Field | Value | | --- | --- | | Journal | BMJ | | Year | 2021 | | PMID | [34642179](https://pubmed.ncbi.nlm.nih.gov/34642179/) | | DOI | [10.1136/bmj.n2321](https://doi.org/10.1136/bmj.n2321) | | Study key | diclofenac_oa | ## Takeaway Topical diclofenac is a safer and effective first-line option for knee osteoarthritis, while some oral NSAIDs are effective but carry higher risks, and opioids generally offer more harm than benefit. ## The question What are the effectiveness and safety profiles of different NSAID, opioid, and paracetamol preparations and doses for knee and hip osteoarthritis pain and physical function? ## Hypothesis The study aimed to identify effective and safe drug options at their lowest possible doses for osteoarthritis. ## Methods This was a systematic review and network meta-analysis of 192 randomized trials, comprising 102,829 participants, published in English with at least 100 patients per group. The trials evaluated NSAIDs, opioids, or paracetamol for osteoarthritis. Data on pain, physical function, and safety outcomes were extracted and assessed for bias. Bayesian random effects models were used for network meta-analysis, comparing active treatments to oral placebo. ## Results Five oral preparations (diclofenac 150 mg/day, etoricoxib 60 and 90 mg/day, rofecoxib 25 and 50 mg/day) had a ≥99% probability of exceeding the minimal clinically relevant pain reduction. Topical diclofenac (70-81 and 140-160 mg/day) had a ≥92.3% probability, while all opioids had a ≤53% probability of achieving this pain reduction. Increased risk of dropouts due to adverse events was observed in 18.5% of oral NSAIDs, 0% of topical NSAIDs, and 83.3% of opioids. An increased risk of any adverse event was found in 29.8% of oral NSAIDs, 0% of topical NSAIDs, and 89.5% of opioids. Oxymorphone 80 mg/day showed the highest risk for dropouts due to adverse events (51%) and any adverse event (88%). ## Conclusion Etoricoxib 60 mg/day and diclofenac 150 mg/day appear to be the most effective oral NSAIDs for osteoarthritis pain and function, but may not be suitable for long-term use or patients with comorbidities due to increased adverse event risk. Topical diclofenac 70-81 mg/day is effective and generally safer, making it a potential first-line treatment for knee osteoarthritis. The harms of opioid treatment for osteoarthritis likely outweigh its clinical benefits. ## Limitations The abstract does not explicitly state limitations of the study beyond the inherent risks associated with certain treatments for specific patient populations. ## Verbatim from the abstract > Topical diclofenac (70–81 and 140–160 mg/day) had ≥92.3% probability of more pronounced treatment effects than the minimal clinically relevant reduction in [osteoarthritis] pain. ## Probability of Treatment Effect Exceeding Minimal Clinically Relevant Pain Reduction | Measure | Probability (%) | | --- | --- | | Oral NSAIDs (5 preparations) | 99 | | Topical Diclofenac (70-81 & 140-160 mg/day) | 92.3 | | All Opioids | 53 | *Probability of different drug categories achieving a more pronounced treatment effect than the minimal clinically relevant reduction in pain.* ## Where this study is used on Magellan This paper is one of the citations behind the evidence grade on the pages below. Grades are assigned from the published research and are independent of affiliate commissions. | Compound or device | Evidence grade | Graded pages | | --- | --- | --- | | Diclofenac Topical Gel | — | — | ## Reference 1. **Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis** BMJ 2021 · [PMID 34642179](https://pubmed.ncbi.nlm.nih.gov/34642179/) · [DOI 10.1136/bmj.n2321](https://doi.org/10.1136/bmj.n2321) > Topical diclofenac (70–81 and 140–160 mg/day) had ≥92.3% probability of more pronounced treatment effects than the minimal clinically relevant reduction in [osteoarthritis] pain. ## Structured data ```json {"@context":"https://schema.org","@graph":[{"@type":"MedicalWebPage","@id":"https://magellanlongevity.com/study/diclofenac_oa.html#page","url":"https://magellanlongevity.com/study/diclofenac_oa.html","name":"Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip…","description":"Topical diclofenac is a safer and effective first-line option for knee osteoarthritis, while some oral NSAIDs are effective but carry higher risks, and…","inLanguage":"en","isPartOf":{"@type":"WebSite","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"author":{"@type":"Person","name":"Gabriel Radu, DO","jobTitle":"Physiatrist (PM&R)","identifier":[{"@type":"PropertyValue","name":"NPI","value":"1376861765"},{"@type":"PropertyValue","name":"NY medical license","value":"275110"}]},"publisher":{"@type":"Organization","name":"Magellan Longevity","url":"https://magellanlongevity.com/"},"encoding":{"@type":"MediaObject","encodingFormat":"text/markdown","contentUrl":"https://magellanlongevity.com/study/diclofenac_oa.md"},"dateModified":"2026-09-02"},{"@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://magellanlongevity.com/"},{"@type":"ListItem","position":2,"name":"Research map","item":"https://magellanlongevity.com/longevity-research-map.html"},{"@type":"ListItem","position":3,"name":"Effectiveness and safety of non-steroidal…","item":"https://magellanlongevity.com/study/diclofenac_oa.html"}]},{"@type":"ScholarlyArticle","@id":"https://magellanlongevity.com/study/diclofenac_oa.html#study","name":"Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis","headline":"Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip…","datePublished":"2021","isPartOf":{"@type":"Periodical","name":"BMJ"},"identifier":"PMID:34642179","url":"https://pubmed.ncbi.nlm.nih.gov/34642179/","sameAs":"https://doi.org/10.1136/bmj.n2321","abstract":"Topical diclofenac is a safer and effective first-line option for knee osteoarthritis, while some oral NSAIDs are effective but carry higher risks, and opioids generally offer more harm than benefit."}]} ``` ## Related on Magellan Longevity - [Longevity research map](https://magellanlongevity.com/longevity-research-map.html) - [Evidence-based longevity supplements](https://magellanlongevity.com/longevity-supplements.md) ## Scope and disclosures Educational information, not medical advice. Nothing here is intended to diagnose, treat, cure, or prevent any disease. Talk to your physician before starting any supplement or device, especially if you are pregnant, nursing, or taking medication. Editorial firewall: evidence grades are assigned from the published research and are independent of any affiliate commission. As an Amazon Associate, Magellan Longevity earns from qualifying purchases. Reviewed for accuracy by a board-certified physician (DO).